Nystatin Cream USP, 15 g recall — Padagis US LLC (Class II)

Padagis US LLC is recorded by the U.S. Food and Drug Administration (FDA) as recalling Nystatin Cream USP, 15 g — a Class II recall, initiated 2026-06-23 and posted to the FDA enforcement report on 2026-07-22, under recall number D-0677-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Subpotent Drug: Low out of specification assay results performed during long-term stability testing.”. From the product description, the form is cream, the strength given is 15 g, the package is described as 15 g tube and it is marked Rx only. 1 National Drug Code number is printed in the record: 45802-059-35. Distribution is recorded as “USA Nationwide” — Nationwide (US), with the recalling firm on record in MN, United States. It is the only recall number the FDA has filed under event ID 99283. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0677-2026
FDA event ID 99283
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Padagis US LLC
Recall initiated 2026-06-23
Reported by FDA 2026-07-22
Report lag 29 days from initiation to report
Distribution USA Nationwide — Nationwide (US)
Firm location on record MN, United States
Product description (source) Nystatin Cream USP, (100,000 USP Nystatin Units), NET WT 15 g, Rx only, 15 g tube, Manufactured by Padagis, Yeruham, Israel, NDC 45802-059-35

Reason reported by FDA

Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

13 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

5 identifying values matched by exact pattern in the 23-word product description above; each is a literal substring of it.

Product named Nystatin Cream USP
Form Cream
Strength 15 g
Package 15 g tube
NDC 45802-059-35
Marketing category Rx only

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
CVS Health, 6.5%D-0678-2026Bell Pharmaceuticals, IncClass II2026-07-22
Clinere, 0.50 mLD-0679-2026Bell Pharmaceuticals, IncClass II2026-07-22
QC Quality Choice, 6.5%D-0680-2026Bell Pharmaceuticals, IncClass II2026-07-22
TopCare Health, 6.5%D-0681-2026Bell Pharmaceuticals, IncClass II2026-07-22
AUDIOLOGIST'S CHOICE, 6.5%D-0682-2026Bell Pharmaceuticals, IncClass II2026-07-22
FAMILY Wellness, 6.5%D-0683-2026Bell Pharmaceuticals, IncClass II2026-07-22
GOOD NEIGHBOR PHARMACY, 6.5%D-0684-2026Bell Pharmaceuticals, IncClass II2026-07-22
LEADER, 6.5%D-0685-2026Bell Pharmaceuticals, IncClass II2026-07-22

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-07-22 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Foster & Thrive, 6.5%D-0686-2026Bell Pharmaceuticals, Inc6.5%2026-07-22
meijer, 6.5%D-0687-2026Bell Pharmaceuticals, Inc6.5%2026-07-22
CAREone, 6.5%D-0688-2026Bell Pharmaceuticals, Inc6.5%2026-07-22
CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL)D-0689-2026Chiesi Usa, Inc.50 mg/100 mL · Injectable Emulsion2026-07-22
BD ChloraPrep Clear, 2%D-0690-2026Carefusion 213, LLC2% · Solution2026-07-22
Methohexital Sodium for Injection, 500 mgD-0662-2026Onesource Specialty Pharma Ltd500 mg · for Injection2026-07-15
Medline Remedy Specialized Silicone Cream (Hydraguard-D ), 59 mLD-0663-2026Biomed Laboratories, Llc.59 mL · Cream2026-07-15
Methohexital Sodium, 100 mg/10 mLD-0664-2026Quva Pharma, Inc.100 mg/10 mL2026-07-15

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 45802-059-35 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Padagis US LLC (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0677-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0677-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-22
Ingested
2026-08-22
Record hash
86d31f7d0edf2b0b

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.